Ayala Pharmaceuticals
General Information | |
Business: |
We are a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. Our differentiated development approach is predicated on identifying and addressing tumorigenic drivers of cancer, through a combination of our bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations. Our current portfolio of product candidates, AL101 and AL102, targets the aberrant activation of the Notch pathway with gamma secretase inhibitors. |
Industry: | BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) |
Employees: | 29 |
Founded: | 2017 |
Contact Information | |
Address | Oppenheimer 4, Rehovot 7670104, Israel |
Phone Number | +972-8-373-1541 |
Web Address | http://www.ayalapharma.com |
View Prospectus: | Ayala Pharmaceuticals |
Financial Information | |
Market Cap | $186.7mil |
Revenues | $2.3 mil (last 12 months) |
Net Income | $-17.8 mil (last 12 months) |
IPO Profile | |
Symbol | AYLA |
Exchange | NASDAQ |
Shares (millions): | 3.7 |
Price range | $15.00 - $15.00 |
Est. $ Volume | $55.0 mil |
Manager / Joint Managers | Citigroup/ Jefferies |
CO-Managers | Oppenheimer & Co./ Raymond James |
Expected To Trade: | 5/8/2020 |
Status: | Priced |
Quiet Period Expiration Date: | Available only to Subscribers |
Lock-Up Period Expiration Date: | Available only to Subscribers |
SCOOP Rating | Available only to Subscribers |
Rating Change | Available only to Subscribers |